

# Nancy K Gillis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6101738/publications.pdf>

Version: 2024-02-01

28  
papers

1,126  
citations

840119

11  
h-index

839053

18  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1944  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Pilot Study Exploring the Link between Donor-Engrafted Clonal Hematopoiesis and Outcomes of Allogeneic Hematopoietic Cell Transplantation from Older Matched Sibling Donors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S306-S307.	0.6	0
2	Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3767-3778.	2.5	13
3	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
4	Cancer and aging: A call to action. <i>Aging and Cancer</i> , 2022, 3, 87-94.	0.5	5
5	COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study. <i>Blood</i> , 2021, 138, 2611-2611.	0.6	0
6	Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 402-402.	0.6	0
7	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
8	Hematopoiesis and Aging. , 2020, , 305-328.		0
9	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
10	Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. <i>JCO Precision Oncology</i> , 2018, 2, 0-0.	1.5	0
11	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. <i>Clinical Cancer Research</i> , 2018, 24, 5918-5924.	3.2	84
12	Hematopoiesis and Aging. , 2018, , 1-24.		0
13	Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12068-12068.	0.8	1
14	Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. <i>Pharmacotherapy</i> , 2017, 37, 1043-1051.	1.2	6
15	Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. <i>Oncologist</i> , 2017, 22, 144-151.	1.9	74
16	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 112-121.	5.1	249
17	Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2021-2023.	0.3	18
18	Chipping in on clonal hematopoiesis. <i>Oncotarget</i> , 2017, 8, 84637-84638.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 115114-115127.	0.8	1
20	The pharmacogenomics of drug resistance to protein kinase inhibitors. <i>Drug Resistance Updates</i> , 2016, 28, 28-42.	6.5	24
21	Abstract 4304: Prevalence and triggers of drug-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a cancer patient cohort. , 2016, , .		0
22	Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly. <i>Blood</i> , 2016, 128, 295-295.	0.6	0
23	Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 269-280.	2.3	62
24	Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 655-657.	2.3	42
25	Pharmacogenetic Evaluation of Targeted Dna Sequencing in Cancer Patients. <i>Annals of Oncology</i> , 2014, 25, iv558.	0.6	0
26	Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. <i>PLoS ONE</i> , 2013, 8, e76984.	1.1	11
27	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 501.	1.0	3
28	Higher genetic diversity in introduced than in native populations of the mussel <i>Mytella charruana</i> : evidence of population admixture at introduction sites. <i>Diversity and Distributions</i> , 2009, 15, 784-795.	1.9	66